Copertina

Editorial: Paradox of liver fat content in the spectrum of non‐alcoholic fatty liver disease

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Sung Won Chung, Jonggi Choi
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	Alimentary Pharmacology & Therapeutics
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Editorial: Variceal Bleeding in Patients Receiving Atezolizumab–Bevacizumab for Hepatocellular Carcinoma—Don't Ignore the Risk Factors! Authors' Reply
di: Jonggi Choi
Pubblicazione: (2025)

Letter: Reflections on the significance of myokines in alcohol‐associated liver disease
di: Yaomin Wang, et al.
Pubblicazione: (2024)

Global epidemiology of alcohol‐associated liver disease in adolescents and young adults
di: Pojsakorn Danpanichkul, et al.
Pubblicazione: (2024)

Myokines are associated with progression, course and mortality in alcohol‐associated liver disease
di: Parminder Kaur, et al.
Pubblicazione: (2024)

Letter: Impact of antiviral treatment on renal function in patients with chronic hepatitis B—Author's reply
di: Hyeyeon Hong, et al.
Pubblicazione: (2024)

Editorial: Sounding the alarm—The rising global burden of adolescent and young adult alcohol‐related liver disease
di: Victoria T. Kronsten, et al.
Pubblicazione: (2024)

Socio‐economic association of alcohol use disorder and cardiovascular and alcohol‐associated liver disease from 2010 to 2019
di: Pojsakorn Danpanichkul, et al.
Pubblicazione: (2024)

Editorial: Crystalising the burden of steatotic liver disease—Authors' reply
di: Carolin V. Schneider, et al.
Pubblicazione: (2024)

Prevalence of at‐risk MASH, MetALD and alcohol‐associated steatotic liver disease in the general population
di: Carolin V. Schneider, et al.
Pubblicazione: (2024)

Global perspective on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis ‐ prevalence, clinical impact, economic implications and management strategies
di: Pegah Golabi, et al.
Pubblicazione: (2024)

Editorial: Updated epidemiology of steatotic liver disease in people with HIV in the United States
di: Richie Manikat, et al.
Pubblicazione: (2024)

Editorial: The tsunami of steatotic liver disease in India, the Asia‐Pacific region and the world
di: Abdel‐Aziz Shaheen, et al.
Pubblicazione: (2024)

Review article: Oesophageal disorders in chronic liver disease
di: Francisco Idalsoaga, et al.
Pubblicazione: (2024)

Editorial: Muscles at the expense of liver injury. Is it worth it?
di: C. Stephens
Pubblicazione: (2024)

Letter: Optimising public health policies to combat alcohol‐associated liver disease in youth—Addressing key methodological and regional challenges
di: Rui Zhang, et al.
Pubblicazione: (2024)

Cardiometabolic criteria as predictors and treatment targets of liver‐related events and cardiovascular events in metabolic dysfunction‐associated steatotic liver disease
di: Nobuharu Tamaki, et al.
Pubblicazione: (2024)

Long‐term clinical outcomes in steatotic liver disease and incidence of liver‐related events, cardiovascular events and all‐cause mortality
di: Nobuharu Tamaki, et al.
Pubblicazione: (2024)

Editorial: The tsunami of steatotic liver disease in India, the Asia‐Pacific region and the world—Authors' reply
di: Manya Prasad, et al.
Pubblicazione: (2024)

UK guideline on the transition and management of childhood liver diseases in adulthood
di: Deepak Joshi, et al.
Pubblicazione: (2024)

Letter: Zinc and selenium—Potential biomarkers for chronic liver disease?
di: Zhuo Li, et al.
Pubblicazione: (2024)

Editorial: The future of managing drug induced liver injury
di: Amanda Nicoll
Pubblicazione: (2024)

Editorial: Updated epidemiology of steatotic liver disease in people withHIVin the United States—Authors' reply
di: Samer Gawrieh, et al.
Pubblicazione: (2024)

Editorial: Using machine learning to predict significant fibrosis in metabolic dysfunction‐associated steatotic liver disease
di: Richie Manikat, et al.
Pubblicazione: (2024)

Metabolic dysfunction‐associated steatotic liver disease and MetALD increases the risk of liver cancer and gastrointestinal cancer: A nationwide cohort study
di: Yewan Park, et al.
Pubblicazione: (2024)

Letter: Prioritising osteosarcopenia assessment in the ongoing care of patients with cholestatic liver diseases
di: Ivan Arcari, et al.
Pubblicazione: (2024)

Prevalence and prognostic value of zinc and selenium deficiency in advanced chronic liver disease
di: Nina Dominik, et al.
Pubblicazione: (2024)

Letter: Use of liver stiffness measurement to identify liver cirrhosis in patients with chronic hepatitis D
di: Jian Wang, et al.
Pubblicazione: (2024)

Letter: Enhancing patient support through social work—Addressing economic challenges and medication non‐adherence in liver disease management
di: Min Wu, et al.
Pubblicazione: (2024)

Steatotic liver disease‐associated all‐cause/cause‐specific mortality in the United States
di: Donghee Kim, et al.
Pubblicazione: (2024)

Letter: Potential impact of Helicobacter pylori infection on oesophageal disorders in chronic liver disease
di: Jannis Kountouras, et al.
Pubblicazione: (2024)

Impacts of glucagon‐like peptide‐1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction‐associated steatotic liver disease cirrhosis and type 2 diabetes
di: Mohamed I. Elsaid, et al.
Pubblicazione: (2024)

Serum growth differentiation factor 15 is a novel biomarker with high predictive capability for liver cancer occurrence in patients with MASLD regardless of liver fibrosis
di: Shusuke Kumazaki, et al.
Pubblicazione: (2024)

Natural history of clinical outcomes and hepatic decompensation in metabolic dysfunction‐associated steatotic liver disease
di: Nabil Noureddin, et al.
Pubblicazione: (2024)

Racial and ethnic disparities in post‐liver transplant outcomes for patients with acute‐on‐chronic liver failure: An analysis of the UNOS database
di: David Uihwan Lee, et al.
Pubblicazione: (2024)

Editorial: Redefining liver health—Personalised approach to assessment of serum ALT in clinical practice
di: Basile Njei, et al.
Pubblicazione: (2024)

The overlap with metabolic dysfunction‐associated steatotic liver disease negatively affects outcomes of primary biliary cholangitis
di: María Hernández‐Pérez, et al.
Pubblicazione: (2024)

Letter: Potential impact ofHelicobacter pyloriinfection on oesophageal disorders in chronic liver disease—Authors' reply
di: Francisco Idalsoaga, et al.
Pubblicazione: (2024)

Characterisation of an outbreak of acute liver injury after ingestion of plant‐based food supplement
di: Gina Choi, et al.
Pubblicazione: (2024)

An algorithm based on immunotherapy discontinuation and liver biopsy spares corticosteroids in two thirds of cases of severe checkpoint inhibitor‐induced liver injury
di: Mar Riveiro‐Barciela, et al.
Pubblicazione: (2024)

Systematic review with meta‐analysis: Steatosis severity and subclinical atherosclerosis in metabolic dysfunction‐associated steatotic liver disease
di: Mohamad Jamalinia, et al.
Pubblicazione: (2024)